These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26344698)

  • 1. Water Proton NMR for In Situ Detection of Insulin Aggregates.
    Taraban MB; Truong HC; Feng Y; Jouravleva EV; Anisimov MA; Yu YB
    J Pharm Sci; 2015 Dec; 104(12):4132-4141. PubMed ID: 26344698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Water Proton NMR: A Tool for Protein Aggregation Characterization.
    Taraban MB; DePaz RA; Lobo B; Yu YB
    Anal Chem; 2017 May; 89(10):5494-5502. PubMed ID: 28440620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Water proton NMR-a sensitive probe for solute association.
    Feng Y; Taraban MB; Yu YB
    Chem Commun (Camb); 2015 Apr; 51(31):6804-7. PubMed ID: 25788228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance to Achieve Accurate Aggregate Quantitation in Biopharmaceuticals by SV-AUC.
    Arthur KK; Kendrick BS; Gabrielson JP
    Methods Enzymol; 2015; 562():477-500. PubMed ID: 26412664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between Dynamic Light Scattering and Size Exclusion High Performance Liquid Chromatography for Monitoring the Effect of pH on Stability of Biopharmaceuticals.
    Al-Ghobashy MA; Mostafa MM; Abed HS; Fathalla FA; Salem MY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():1-9. PubMed ID: 28578190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals.
    Berkowitz SA
    AAPS J; 2006 Sep; 8(3):E590-605. PubMed ID: 17025277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nondestructive Quantitative Inspection of Drug Products Using Benchtop NMR Relaxometry-the Case of NovoMix® 30.
    Briggs KT; Taraban MB; Wang W; Yu YB
    AAPS PharmSciTech; 2019 May; 20(5):189. PubMed ID: 31111256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Water Proton NMR to Characterize Protein Aggregates: Gauging the Response and Sensitivity.
    Taraban MB; DePaz RA; Lobo B; Yu YB
    Anal Chem; 2019 Mar; 91(6):4107-4115. PubMed ID: 30767509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case study and use of sedimentation equilibrium analytical ultracentrifugation as a tool for biopharmaceutical development.
    Varley PG; Brown AJ; Dawkes HC; Burns NR
    Eur Biophys J; 1997; 25(5-6):437-43. PubMed ID: 9188166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inspecting Insulin Products Using Water Proton NMR. I. Noninvasive vs Invasive Inspection.
    Taraban MB; Wang Y; Briggs KT; Yu YB
    J Diabetes Sci Technol; 2022 Nov; 16(6):1410-1418. PubMed ID: 34111968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some Lessons Learned From a Comparison Between Sedimentation Velocity Analytical Ultracentrifugation and Size Exclusion Chromatography to Characterize and Quantify Protein Aggregates.
    Gandhi AV; Pothecary MR; Bain DL; Carpenter JF
    J Pharm Sci; 2017 Aug; 106(8):2178-2186. PubMed ID: 28479353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of NMR and Dynamic Light Scattering for Measuring Diffusion Coefficients of Formulated Insulin: Implications for Particle Size Distribution Measurements in Drug Products.
    Patil SM; Keire DA; Chen K
    AAPS J; 2017 Nov; 19(6):1760-1766. PubMed ID: 28791599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical review of methods for size characterization of non-particulate protein aggregates.
    Philo JS
    Curr Pharm Biotechnol; 2009 Jun; 10(4):359-72. PubMed ID: 19519411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust quantitation of basic-protein higher-order aggregates using size-exclusion chromatography.
    Gervais D; Downer A; King D; Kanda P; Foote N; Smith S
    J Pharm Biomed Anal; 2017 May; 139():215-220. PubMed ID: 28292680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Particle sizing methods for the detection of protein aggregates in biopharmaceuticals.
    Khodabandehloo A; Chen DD
    Bioanalysis; 2017 Feb; 9(3):313-326. PubMed ID: 28098491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of surfaces and leachables on the stability of biopharmaceuticals.
    Bee JS; Randolph TW; Carpenter JF; Bishop SM; Dimitrova MN
    J Pharm Sci; 2011 Oct; 100(10):4158-70. PubMed ID: 21523787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is any measurement method optimal for all aggregate sizes and types?
    Philo JS
    AAPS J; 2006 Sep; 8(3):E564-71. PubMed ID: 17025274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Sizes of Aggregates of Insulin Analogs and the Conformations of the Constituent Protein Molecules: A Concomitant Dynamic Light Scattering and Raman Spectroscopy Study.
    Zhou C; Qi W; Lewis EN; Carpenter JF
    J Pharm Sci; 2016 Feb; 105(2):551-558. PubMed ID: 26869418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Streamlined Bioanalytical Approach to Select a Compatible Primary Container System Early in Drug Development: A Toolbox for the Biopharmaceutical Industry.
    Singh R; Waxman L
    J Pharm Sci; 2020 Jan; 109(1):206-210. PubMed ID: 31545968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of aggregates in therapeutic proteins using sedimentation velocity analytical ultracentrifugation: practical considerations that affect precision and accuracy.
    Pekar A; Sukumar M
    Anal Biochem; 2007 Aug; 367(2):225-37. PubMed ID: 17548043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.